Extended Data Fig. 2: Clinical subtype and molecular subtype distribution according to site of metastasis. | Nature Cancer

Extended Data Fig. 2: Clinical subtype and molecular subtype distribution according to site of metastasis.

From: Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis

Extended Data Fig. 2

a. Distribution of the 55 diagnosed primary tumors (n = 39 primaries) by clinical receptor status (TNBC, ER+/HER2-, HER2+, and unknown, left side) linked to their anatomic sites of metastasis (n = 63 metastases). Clinical receptor status at the time of first primary diagnosis (‘First Primary Receptors’ column of Supplementary Table 2). b. Distribution of 39 diagnosed primary tumors by gene expression-based intrinsic molecular subtype when available (left) linked to their anatomic sites of metastasis (right). c. TNBC and non-TNBC subtype proportions of primary (left, n = 39 primaries) and paired metastatic (right, n = 64 metastases) tumors by TNBCtype25. d. Comparison of subtype classifications between TNBC subtype and PAM50 of primary (left, 39 primaries) and paired metastatic (right, 63 metastases) tumors. LumA, Luminal A; LumB, Luminal B; CL, Claudin-low; NL, normal-like; BL1, basal-like 1; BL2, basal-like 2; IM, immunomodulatory; LAR, luminal androgen receptor; M, mesenchymal-like; MSL, mesenchymal stem-like.

Back to article page